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Background: The NHS spends billions of pounds annually on repeat prescriptions in primary care, but data on their
extent and use is out of date. Understanding the scale of repeat prescribing and for whom it is prescribed is
important for the NHS to plan services and develop policies to improve patient care.
Method: Anonymous data on prescription numbers and practice population demographics was obtained from
GP computer systems in a large urban area.
Searches were conducted in November 2011 to identify the numbers of repeat items listed on individuals’ repeat
lists by sex and age.
The proportion of all prescription items issued as repeats was identified by conducting searches on items issued as
repeat and acute prescriptions.
Results: In the year of study 4,453,225 items were issued of which 3,444,769 (77%) were repeats (mean 13 items
per patient/annum) and 1,008,456 (23%) acute prescriptions (mean 3.9 items per patient per annum). The mean
number of repeat Items per patient was 1.87 (range 0.45 ages 0-9 years; 7.1 ages 80-89 years). At least one repeat
medicine was prescribed to 43% of the population (range 20% for ages 0-9; over 75% for ages 60+).
Conclusion: A significant proportion of the population receive repeat prescriptions and the proportion increases
with age. Whilst the proportion of repeat items to acute items has remained unchanged over the last two decades
the number of repeat prescriptions items issued has doubled (from 5.8 to 13.3 items/patient/annum). This has
implications for general practice workload, patient convenience, NHS costs and risk.
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In the UK most NHS patients receive medicines
intended for long-term use as “repeat prescriptions”.
These are prescription items that are generated without
the need for a consultation from a list of authorised re-
peat medicines. It is a truth universally acknowledged
[1,2] but not justified with any recent evidence, that the
proportion of the population on repeat medication is
high and increasing. As Avery notes [3], evidence on the
prevalence of repeat medication is almost all out of date.
Harris and Dajda used data from a four year period to
1994 to report that 48% of patients had at least one re-
peat medication and that repeats accounted for 75% of
items and 81% of costs [4]. Since then there have been* Correspondence: d.petty@leeds.ac.uk
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quality of GP prescribing had to use these 17-year-old
data [2]. It is remarkable that there is such a dearth of
data on an activity that exposes patients to the risks as
well as the benefits of so many medicines and accounts
for many billions of pounds of NHS resource.
This paper provides an update on the extent of repeat
medication prescribing in a population of a large urban
area in the North of England.Method
We employed a cross sectional design using data from
general practices in Bradford and Airedale Primary Care
Trust (PCT) in West Yorkshire. The PCT had 79 prac-
tices. We approached a convenience sample of 29 prac-
tices. These practices were used because they all had a
practice pharmacy services enabling access to practiced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of the 29 practices were larger than non-study practices
but did not differ in terms of age, sex and deprivation (see
Table 1). Practice consent was obtained to use anonymous
data on prescription numbers and practice population
demographics. All practices in the PCT used SystmOne
(TPP Ltd), which lists medicines authorised for repeat use
on a “repeat template”. We defined a repeat medicine as
any medicine on a repeat template. Searches were con-
ducted in November 2011 at practice population level to
identify the numbers of repeat items listed on individual’s
repeat template. The mean number of repeat prescriptions
items per patient was calculated for each ten-year age/sex
band by dividing the total number of repeat medicines
listed by the population. To identify the total number of
items issued per patient searches were constructed on
SystmOne that identified whether an issue was an “acute
medication” issue or issued from the patient’s “repeat tem-
plate” in the financial year 2011/12. Repeat issues were
then expressed as a proportion of all issues (repeats and
acutes).Results
Patients, practices, total prescriptions issued
All 29 of the practices approached consented to using
their data. A comparison of study practices’ verse non-
study practices’ demographics in the same PCT is shown
in Table 1.
The aggregate number of repeat prescription items listed
on individual patients repeat lists was 483,431. In the year
of study 4,453,225 items were issued of which 3,444,769
were repeat prescriptions (77%) (13.1 items per patient per
annum) and 1,008,456 (23%) (mean 3.8 items per patient
per annum) as acute prescriptions. The median percentage
of repeat prescription items (of total prescription items)
across all the age/sex bands was 77% (IQR 73-80%) (mini-
mum 67%, maximum 87%).Patients on at least one medicine
Forty-three per cent of the population was prescribed at
least one repeat medicine. This figure ranged from 20%Table 1 Comparison of consenting (study) and other PCT
practice demographics
Study
practices
Other
practices
Number of practices 29 50
Total population 262,933 290,821
List size: mean (SD) 9066 (4359) 5816 (2837)
Age: mean (SD) 34 (5.0) 36 (5.8)
% female 50.1% 50.1%
Index of multiple deprivation: mean (SD) 34.4 (11.8) 37.7 (14.7)for the 0-9 year olds to over 75% for the over 60s
(Figure 1).
Overall (including patients on no medicines in the
denominator) the mean number of repeats Items per pa-
tient on practice lists was 1.9.
Number of repeat items by age and sex
Of those patients on at least one repeat medicine the
mean number of repeat medicines per patient was 4.3
(Figure 2).
Discussion
Our study is a comparatively small one compared with
Harris and Dajda (who were able to sample data from
the whole of England). Nonetheless we believe our sam-
ple, though only from one geographical area, is suffi-
ciently large to allow guarded comparison, especially as
there are no other currently available data. This study
demonstrates the extent of change in both the total
quantity of repeat prescribing items and the age sex dis-
tribution of their use since Harris and Dajda’s report of
data from 17-18 years before (4). The proportion of pa-
tients on repeat medicines is lower than that reported by
Harris and Dajda being 43% compared to 48%. The pro-
portion of children and young adults on repeats in our
study was 25% compared to 35% with Harris and Dajda’s
study The proportion of older adults on repeats is the
same ranging from around 75% in the 60+ group to over
90% in the over 70s. Close comparison between our
study and that of Harris and Dajda is not warranted as
our study used a local sample compared to a national
sample.
It is only when the number of items per patient is com-
pared that a large increase is seen. Our study recorded 13
issued items per patient per annum, compared with 5.8
issues for Harris and Dajda [4]. In England in 2011 an
average of 18.7 prescription items were dispensed per
head of population [5].
Many Primary Care Trusts in England have recom-
mended restricting prescription length to 28 days on
the advice of the National Prescribing Centre and the
Department of Health [6] as a result prescription dura-
tions have been shown to have reduced between 1998 and
2009 [7]. The cost benefit of shorter prescription dura-
tions has been questioned [6,7] because of only a limited
effect on reducing waste but with a large increase in dis-
pensing costs [7]. The policy to reduce prescription length
may also have resulted in more inconvenience for patients
and a greater work load for them in ordering their sup-
plies [8]. Our data shows that the majority of older people
are on a repeat prescription and therefore are dispropor-
tionately affected by polices for 28 day prescribing.
The study was conducted in one large urban area in
Northern England. Less than half of practices participated,
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Figure 1 The percentage of patients receiving at least one repeat prescription, by age and sex.
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number of practices and patients participating was suf-
ficient to give a guide as to major prescribing trends.
Although our study practices were larger than non-study
practices they were similar in terms of age and deprivation
scores, which are the two largest determinants of pres-
cribing variation [9-11]. Although this study was on a
relatively small scale in one English city we believe the
prescribing rates are likely to be typical of the UK because
our consenting practices covered a wide socio-economic
and cultural range of population and included both small
and large practices. A more complex study on a larger
scale exploring the population and drug types prescribed
in greater detail would be valuable to track the epide-
miology of drug use.
Some practices do not record all long-term medica-
tion on repeat templates. In particular, oral contracep-
tion is often prescribed as a six month supply without
adding it to the repeat template. Some practices are re-
luctant to include potentially harmful medicines that
need frequent monitoring (such as methotrexate) on the
repeat template.Figure 2 Mean number of medicines per patient on repeats.Although we did not collect data about individual
groups of drugs, the figures for overall dispensing of medi-
cines from the NHS Business Authority give some indica-
tion of the growth areas [12]. Cardiovascular drugs and
endocrine drugs are the areas of highest growth, and it is
likely that the development of evidence-based guidelines,
commencing with the National Service Framework for
Coronary Heart Disease in 2000 and followed by NICE
guidelines, SIGN guidelines and British Hypertension
Society Guidelines to name only a few will have influenced
the process. The Quality and Outcomes Framework for
General Practice, which began in 2004, encouraged GPs to
be more methodical and inclusive in case-finding and
treatment, will also have fuelled change [13].
The implication of these evidence-based changes is that
they represent quality prescribing. The more medicines
taken, however, the greater the risk of harm from adverse
drug events, and the reports of drug-related hospital ad-
missions suggesting that over 6% of acute admissions re-
sult from therapeutic misadventure sound a warning of
the need to be circumspect about polypharmacy [14,15].
The continuation of so many drugs into later ages also
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particularly when evidence of efficacy or safety is seldom
derived from clinical trials in the old and the potential to
extend life expectancy may no longer be the priority.
Therapeutic momentum, where drugs are continued
beyond their need merely because no-one has had the
thought (or perhaps the courage) to stop them is a poten-
tially important risk.
All UK general practices have systems to electronically
manage and generate repeat prescriptions. Previous stu-
dies have shown problems in the control of these systems
including deficiencies in the authorisation and review of
repeats by doctors [16] and the issuing of medicines
(which are not repeats) by receptionists [1]. A report for
the General Medical Council on the prevalence and causes
of prescribing errors in general practice found a high fre-
quency of errors [17]. One of their recommendations was
that general practices review the procedures they have in
place for repeat prescribing, medication monitoring and
medication reviews. Since the majority of prescriptions are
prescribed as repeats this recommendation would have a
high impact of patient safety.
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Conclusion
A significant proportion of the population receive repeat
prescriptions and the proportion increases with age.
Whilst the proportion of repeat items to acute items has
remained unchanged over the last two decades the num-
ber of repeat prescriptions items issued has doubled
(from 5.8 to 13.3 items/patient/annum). This has impli-
cations for general practice workload, patient conveni-
ence, NHS costs and risk.
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